INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒═══════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                 │ CHIA Criteria                                     │   Score │
╞═══════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ Symptoms of ischaemia                             │ Symptoms of ischaemia                             │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ New or presumed new significant ST-T wave changes │ New or presumed new significant ST-T wave changes │     100 │
├───────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Imaging evidence of new or presumed new loss of   │ Imaging evidence of new or presumed new loss of   │     100 │
│ viable myocardium or regional wall motion         │ viable myocardium or regional wall motion         │         │
│ abnormality                                       │ abnormality                                       │         │
╘═══════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤═══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                     │   Score │
╞════════════════════════════════════════════════════╪═══════════════════════════════════════════════════╪═════════╡
│ (2)                                                │ Symptoms of ischaemia                             │       0 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Acute ST-segment elevation myocardial infarction   │ Imaging evidence of new or presumed new loss of   │      32 │
│ (STEMI) A. ※ STEMI: "ST-segment elevation ≥0.1 mV  │ viable myocardium or regional wall motion         │         │
│ in ≥2 contiguous leads B. or documented newly      │ abnormality                                       │         │
│ developed left bundle-branch block "               │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 19 Years                  │ New or presumed new significant ST-T wave changes │      32 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ A. ※ NSTEMI: NSTEMI is defined as a combination of │ Imaging evidence of new or presumed new loss of   │      33 │
│ criteria with mandated elevation of a cardiac      │ viable myocardium or regional wall motion         │         │
│ biomarker, preferably high-sensitive cardiac       │ abnormality                                       │         │
│ troponin with at least one value above 99th        │                                                   │         │
│ percentile of the upper reference limit and at     │                                                   │         │
│ least one of the following                         │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Intracoronary thrombus detected on angiography     │ Symptoms of ischaemia                             │      33 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Subject is able to verbally confirm understandings │ Imaging evidence of new or presumed new loss of   │      33 │
│ of risks, benefits and treatment alternatives of   │ viable myocardium or regional wall motion         │         │
│ receiving invasive physiologic evaluation and PCI  │ abnormality                                       │         │
│ and he/she or his/her legally authorized           │                                                   │         │
│ representative provides written informed consent   │                                                   │         │
│ prior to any study related procedure               │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Primary percutaneous coronary intervention (PCI)   │ Imaging evidence of new or presumed new loss of   │      34 │
│ in \< 12 h after the onset of symptoms for STEMI   │ viable myocardium or regional wall motion         │         │
│ patients (In case of NSTEMI, PCI should be         │ abnormality                                       │         │
│ performed within 72 hours of symptom onset)        │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Chronic total occlusion in non-IRA                 │ Development of pathological Q waves on ECG        │      34 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Pregnancy or breast feeding                        │ New or presumed new significant ST-T wave changes │      34 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Severe stenosis with TIMI flow ≤ II of the non-IRA │ Development of pathological Q waves on ECG        │      36 │
│ artery                                             │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Non-IRA stenosis not amenable for PCI treatment by │ Imaging evidence of new or presumed new loss of   │      37 │
│ operators' decision)                               │ viable myocardium or regional wall motion         │         │
│                                                    │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Non-cardiac co-morbid conditions are present with  │ Imaging evidence of new or presumed new loss of   │      37 │
│ life expectancy \<1 year or that may result in     │ viable myocardium or regional wall motion         │         │
│ protocol non-compliance (per site investigator's   │ abnormality                                       │         │
│ medical judgment)                                  │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Patients with a history of Coronary Artery Bypass  │ Imaging evidence of new or presumed new loss of   │      37 │
│ Graft (CABG) or treated with fibrinolytic Therapy  │ viable myocardium or regional wall motion         │         │
│                                                    │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Unprotected left main coronary artery disease      │ Imaging evidence of new or presumed new loss of   │      38 │
│ (stenosis \> 50% by visual estimation)             │ viable myocardium or regional wall motion         │         │
│                                                    │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Other primary valvular disease with severe degree: │ Imaging evidence of new or presumed new loss of   │      38 │
│ severe mitral regurgitation, mitral stenosis,      │ viable myocardium or regional wall motion         │         │
│ severe aortic regurgitation, or aortic stenosis    │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Unwillingness or inability to comply with the      │ Imaging evidence of new or presumed new loss of   │      38 │
│ procedures described in this protocol              │ viable myocardium or regional wall motion         │         │
│                                                    │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Subject must be at least 19 years of age           │ Development of pathological Q waves on ECG        │      39 │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Acute non-ST-segment elevation myocardial          │ Development of pathological Q waves on ECG        │      39 │
│ infarction (NSTEMI)                                │                                                   │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Multivessel disease (at least one stenosis of      │ Imaging evidence of new or presumed new loss of   │      39 │
│ \>50% in a non-culprit vessel ≥ 2.0 mm by visual   │ viable myocardium or regional wall motion         │         │
│ estimation)                                        │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Cardiogenic shock (Killip class IV) already at     │ Imaging evidence of new or presumed new loss of   │      39 │
│ presentation or the completion of IRA PCI          │ viable myocardium or regional wall motion         │         │
│                                                    │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Known true anaphylaxis to contrast medium (not     │ Imaging evidence of new or presumed new loss of   │      41 │
│ allergic reaction but anaphylactic shock)          │ viable myocardium or regional wall motion         │         │
│                                                    │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Intolerance to Aspirin, Clopidogrel, Plasugrel,    │ Imaging evidence of new or presumed new loss of   │      42 │
│ Ticagrelor, Heparin, Bivaluridin, or Everolimus,   │ viable myocardium or regional wall motion         │         │
│ Zotarolimus                                        │ abnormality                                       │         │
├────────────────────────────────────────────────────┼───────────────────────────────────────────────────┼─────────┤
│ Development of pathological Q waves on             │ Development of pathological Q waves on ECG        │      79 │
│ electrocardiography (ECG)                          │                                                   │         │
╘════════════════════════════════════════════════════╧═══════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════╤════════════════════════════════════════════╤═════════╕
│ Personal Criteria                      │ CHIA Criteria                              │   Score │
╞════════════════════════════════════════╪════════════════════════════════════════════╪═════════╡
│ Chronic total occlusion in non-IRA     │ NA                                         │       6 │
├────────────────────────────────────────┼────────────────────────────────────────────┼─────────┤
│ Development of pathological Q waves on │ Development of pathological Q waves on ECG │      79 │
│ electrocardiography (ECG)              │                                            │         │
╘════════════════════════════════════════╧════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 16
Average Levenshtein Ratio of individual lines: 43.892857142857146
OverAll Ratio: 29.946428571428573
